PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
08 mars 2024 16h15 HE
|
PharmAla Biotech
PharmAla provides corporate update following AGM
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
07 juin 2023 08h07 HE
|
Concerned Shareholders of Company MindMed
FCM Confident in Ability to Start MM-120 Phase III in 2023 and Obtain FDA Approval In 2026 Dr. Freeman and Other FCM Directors Pledge to Extend Lockup Period For Selling Shares Until June 15, 2026 ...
ISS Appears to Rely on MindMed's False and Misleading Statements to Justify the Company's Abysmal Performance; Seemingly Ignores MindMed's Apparent Disregard of Patient Safety
05 juin 2023 06h19 HE
|
Concerned Shareholders of Company MindMed
ISS Dismissed 47% Stock Price Drop Following September 2022 Financing as In Line with “Sectoral Trends”, in a Baffling Lack of Critical Analysis and Seemingly in Opposition to the Factual...
World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board
30 mai 2023 08h00 HE
|
Incannex Healthcare
Highlights: Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.Dr. Bill Richards is among the world’s best known psychedelic researchers and practitioners. He has...
Does Microdosing Impact Meditation? New Study From Beckley Foundation and Quantified Citizen Investigates
15 sept. 2022 13h15 HE
|
Quantified Citizen
VANCOUVER, British Columbia, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Microdosing and Meditation Study, led by Beckley Foundation in collaboration with Psychedelic Data Society and Quantified Citizen...
Enzyme Replacement Therapy Market Worth $15.18 Billion by 2028 at 6.8% CAGR Led by Hospitals Segment (49% Market Share in 2021) Global Analysis by The Insight Partners
22 juil. 2022 07h35 HE
|
The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics
20 juin 2022 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, June 20, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural,...
Franciosi Consulting Reviewing the Use of Psilocybin for Treating Depression, Anxiety and Addiction
06 janv. 2022 14h00 HE
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi has been reviewing the science and history of psychedelic drugs for treating depression, anxiety and addiction....
Optimi Health and Numinus Wellness Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application
11 mai 2021 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional...
MagicMed Industries to Present at the Q1 Virtual Investor Summit
19 mars 2021 08h15 HE
|
MagicMed Industries Inc.
CALGARY, Alberta, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- MagicMed Industries Inc. ("MagicMed" or the "Company"), a biotechnology company focused on creating novel psychedelic...